Literature DB >> 23513028

Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum.

Caroline G Baxter1, Riina Rautemaa, Andrew M Jones, A Kevin Webb, Matthew Bull, Eshwar Mahenthiralingam, David W Denning.   

Abstract

BACKGROUND: Pseudomonas aeruginosa and Aspergillus fumigatus frequently co-colonise the airways of patients with cystic fibrosis (CF). This study aimed to assess the impact of short-term administration of intravenous antipseudomonal antibiotics during CF exacerbations on the presence of Aspergillus.
METHODS: Pre- and post-antibiotic sputum samples from 26 adult patients with CF and chronic Pseudomonas colonisation were analysed for the presence of Aspergillus by fungal culture, real-time PCR and galactomannan antigen (GM). Lung function (forced expiratory volume in 1 s and forced vital capacity % predicted) and blood levels of total IgE, specific A fumigatus IgE and specific A fumigatus IgG were measured at the start and end of antibiotics. Respiratory viral real-time PCR and bacterial community profiling using ribosomal intergenic spacer analysis (RISA) were performed to estimate concurrent changes in the lung microbiome.
RESULTS: Aspergillus PCR and GM were more sensitive than culture in detecting Aspergillus species (culture 8%, GM 31%, PCR 77%). There was a significant decline in the presence of Aspergillus, measured both by PCR and GM index, following antibacterial therapy (PCR: median increase in crossing threshold 1.7 (IQR 0.5-3.8), p<0.001; GM: median fall in GM index 0.7 (IQR 0.4-1.6), p=0.016). All patients improved clinically with a significant increase in lung function (p<0.0001). RISA community analysis showed large changes in bacterial community similarity in 67% of patients following antibiotics. Viral RT-PCR demonstrated the presence of a concurrent respiratory virus in 27% of patients.
CONCLUSIONS: Intravenous antibiotics targeting Pseudomonas during CF pulmonary exacerbations have a negative impact on the presence of Aspergillus in sputum samples.

Entities:  

Keywords:  Aspergillus Lung Disease; Cystic Fibrosis; Respiratory Infection

Mesh:

Substances:

Year:  2013        PMID: 23513028     DOI: 10.1136/thoraxjnl-2012-202412

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  31 in total

Review 1.  Fungal Pathogens in CF Airways: Leave or Treat?

Authors:  A Singh; A Ralhan; C Schwarz; D Hartl; A Hector
Journal:  Mycopathologia       Date:  2017-08-02       Impact factor: 2.574

2.  Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis.

Authors:  William G Flight; Ann Smith; Christopher Paisey; Julian R Marchesi; Matthew J Bull; Phillip J Norville; Ken J Mutton; A Kevin Webb; Rowland J Bright-Thomas; Andrew M Jones; Eshwar Mahenthiralingam
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

3.  Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity.

Authors:  Brendan D Snarr; Perrin Baker; Natalie C Bamford; Yukiko Sato; Hong Liu; Mélanie Lehoux; Fabrice N Gravelat; Hanna Ostapska; Shane R Baistrocchi; Robert P Cerone; Elan E Filler; Matthew R Parsek; Scott G Filler; P Lynne Howell; Donald C Sheppard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-20       Impact factor: 11.205

Review 4.  The microbiome-metabolome crosstalk in the pathogenesis of respiratory fungal diseases.

Authors:  Samuel M Gonçalves; Katrien Lagrou; Cláudio Duarte-Oliveira; Johan A Maertens; Cristina Cunha; Agostinho Carvalho
Journal:  Virulence       Date:  2016-11-07       Impact factor: 5.882

5.  Aspergillus Bronchitis in Patients with Cystic Fibrosis.

Authors:  Claudia Brandt; Jobst Roehmel; Volker Rickerts; Volker Melichar; Nadja Niemann; Carsten Schwarz
Journal:  Mycopathologia       Date:  2017-08-17       Impact factor: 2.574

6.  Concomitant presence of Aspergillus fumigatus and Stenotrophomonas maltophilia in the respiratory tract: a new risk for patients with liver disease?

Authors:  Odile Cabaret; Christine Bonnal; Florence Canoui-Poitrine; Aurélie Emirian; Geoffray Bizouard; Eric Levesque; Bernard Maitre; Vincent Fihman; Jean-Winoc Decousser; Françoise Botterel
Journal:  J Med Microbiol       Date:  2016-02-12       Impact factor: 2.472

7.  Use of Selective Fungal Culture Media Increases Rates of Detection of Fungi in the Respiratory Tract of Cystic Fibrosis Patients.

Authors:  Gina Hong; Heather B Miller; Sarah Allgood; Richard Lee; Noah Lechtzin; Sean X Zhang
Journal:  J Clin Microbiol       Date:  2017-01-18       Impact factor: 5.948

8.  Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis.

Authors:  Gina Hong; Kevin J Psoter; Mark T Jennings; Christian A Merlo; Michael P Boyle; Denis Hadjiliadis; Steven M Kawut; Noah Lechtzin
Journal:  J Cyst Fibros       Date:  2018-02-12       Impact factor: 5.482

Review 9.  Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways.

Authors:  Sanjay H Chotirmall; Maria Teresa Martin-Gomez
Journal:  Mycopathologia       Date:  2017-05-17       Impact factor: 2.574

10.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.